Context Therapeutics Inc. Expected to Post Q3 2024 Earnings of ($0.16) Per Share (NASDAQ:CNTX)

Context Therapeutics Inc. (NASDAQ:CNTX) – Analysts at HC Wainwright reduced their Q3 2024 earnings estimates for shares of Context Therapeutics in a research note issued to investors on Monday, September 23rd. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.16) for the quarter, down from their previous estimate of ($0.03). HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q4 2024 earnings at ($0.10) EPS, FY2024 earnings at ($0.52) EPS, FY2025 earnings at ($0.36) EPS, FY2026 earnings at ($0.50) EPS, FY2027 earnings at ($0.62) EPS and FY2028 earnings at ($0.70) EPS.

Context Therapeutics Trading Up 0.5 %

Shares of NASDAQ:CNTX opened at $1.86 on Thursday. The company has a 50 day moving average of $2.30 and a 200 day moving average of $1.90. The stock has a market cap of $139.50 million, a P/E ratio of -1.40 and a beta of 2.31. Context Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Great Point Partners LLC purchased a new stake in shares of Context Therapeutics in the second quarter worth $14,876,000. Blue Owl Capital Holdings LP purchased a new stake in shares of Context Therapeutics in the 2nd quarter valued at about $10,348,000. Driehaus Capital Management LLC bought a new stake in shares of Context Therapeutics during the 2nd quarter valued at about $4,527,000. Nantahala Capital Management LLC purchased a new position in shares of Context Therapeutics during the second quarter worth about $3,881,000. Finally, Affinity Asset Advisors LLC grew its holdings in shares of Context Therapeutics by 392.4% during the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after purchasing an additional 1,290,323 shares in the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.